Introduction
============

Lipid emulsion was originally developed for parenteral nutrition in the 1960s [@B1]. However, lipid emulsion is currently used to treat local anesthetic-induced systemic toxicity [@B2]-[@B6]. Carnitine helps transport long-chain fatty acids into the mitochondria [@B7]-[@B9]; carnitine-acylcarnitine translocase transports long-chain acyl-carnitine into the mitochondrial matrix and returns carnitine to the cytoplasm [@B9]. β-Oxidation produces adenosine triphosphate (ATP) in cardiac mitochondria using long-chain fatty acids as the major energy source of the heart [@B9]. Bupivacaine prevents long-chain fatty acid transport to the mitochondria by inhibiting carnitine-acylcarnitine translocase [@B8]-[@B10]. Pretreatment with L-carnitine before bupivacaine-induced asystole in rats decreased the susceptibility to bupivacaine-induced cardiac toxicity [@B11]. In 1997, Weinberg et al. reported that subcutaneous injection of a small dose of bupivacaine (non-toxic dose: 22 mg) in a 16-year-old female patient with isovaleric acidemia yielded unexpected ventricular arrhythmia likely caused by secondary systemic carnitine deficiency [@B7]. Based on these reports, this unexpected ventricular arrhythmia was likely associated with increased susceptibility to bupivacaine toxicity due to carnitine deficiency [@B7]-[@B11]. In addition, Wong et al. reported ventricular arrhythmia caused by the presumed intravascular migration of an epidural catheter in a 6-year-old male patient with both secondary carnitine deficiency due to long-term treatment with valproic acid and a non-toxic dose of bupivacaine (0.58 mg/ml) [@B12]. Pretreatment with lipid emulsion reportedly increased the dosage of bupivacaine needed to produce asystole in rats, and a mixture of Intralipid® and plasma containing bupivacaine produced a high lipid-to-aqueous-phase ratio of bupivacaine (11.9 ± 1.77), suggesting that Intralipid® has a high capacity to bind bupivacaine [@B13]. Moreover, Intralipid® improved the survival and hemodynamics of bupivacaine-induced cardiac toxicity in dogs [@B14]. The administration of lipid emulsion affected the central nervous system toxicity induced by local anesthetics by increasing the dosage of bupivacaine and levobupivacaine needed to produce convulsion in awake rats [@B15]. Rosenblatt et al. reported the first clinical case of lipid emulsion for treating presumed bupivacaine toxicity in 2006 [@B16]. The treated patient, a 58-year-old male with seizure and asystole due to toxicity from bupivacaine and mepivacaine used in an interscalene brachial plexus block, was unresponsive to advanced cardiac life support, but lipid emulsion led to recovery [@B16]. Moreover, the first clinical case of lipid emulsion resuscitation of a patient with toxicity induced by a non-local anesthetic drug was reported in 2008: Intralipid® infusion led to the recovery of a 17-year-old female patient with severe cardiovascular depression and seizure due to toxic doses of bupropion and lamotrigine [@B17]. According to reviews of many clinical case reports and laboratory studies, lipid emulsion can effectively treat cardiovascular collapse caused by a toxic dose of local anesthetics [@B2]-[@B5]. Specifically, toxicity of bupivacaine among local anesthetics is most amenable to lipid emulsion treatment [@B2]-[@B4].

Proposed mechanisms
===================

The widely accepted lipid sink theory proposes a mechanism responsible for lipid emulsion-mediated resuscitation in cases of systemic toxicity induced by local anesthetics. This theory states that highly lipid-soluble drugs, including local anesthetics and non-local anesthetic drugs, are absorbed into the lipid emulsion of the plasma and removed from tissues affected by toxicity [@B6]. Lipid emulsion (Intralipid®) enhanced bupivacaine removal from cardiac tissues following bupivacaine (a highly lipid-soluble local anesthetic)-induced asystole in isolated rat hearts and did so with improved hemodynamics [@B18]. Pretreatment with Intralipid® increased the lethal dose in rats and enhanced the total bupivacaine concentration of the lipid emulsion in plasma during asystole [@B13]. Moreover, Intralipid® improved the rate pressure product during resuscitation of bupivacaine-induced asystole in isolated rat hearts using the Langendorff preparation [@B19]. In this study, lipid emulsion produced both a concomitant reduction in myocardial bupivacaine in a concentration-dependent manner and a better early response than late response during recovery [@B19]. Pretreatment with lipid emulsion increased the time required to produce bupivacaine-induced asystole, and post-treatment with lipid emulsion shortened the recovery time from bupivacaine-induced cardiac arrest in a Langendorff isolated rat heart model [@B20],[@B21]. In contrast, pretreatment with lipid emulsion did not significantly alter the time required to produce mepivacaine-induced asystole, and post-treatment with lipid emulsion had no effect on the recovery time from ropivacaine-and-mepivacaine-induced cardiac arrest [@B20],[@B21]. Although post-treatment with lipid emulsion in an isolated Langendorff heart model has several limitations, including the use of a buffer solution with only lipid emulsion and no local anesthetics, these results support the lipid sink theory [@B20]-[@B22]. Considering the lipid solubility of local anesthetics (log \[octanol/ buffer partition coefficient\] at pH 7.4; bupivacaine \[2.539\], ropivacaine \[2.060\], lidocaine \[1.633\] and mepivacaine \[1.322\]), these previous reports indicate a relatively high sequestration of the highly lipid-soluble local anesthetic bupivacaine by lipid emulsion [@B13],[@B14],[@B18]-[@B21],[@B23]. Intralipid® accelerated the recovery of contractility in stimulated myocardial contraction in a guinea pig model, with a reduction in the myocardial bupivacaine content from a toxic dose causing asystole [@B24]. In another study, lipid emulsion decreased the plasma concentration of the drug, with a higher lipid solubility or a larger distribution volume [@B25]. Lipid emulsion attenuated bupivacaine- and mepivacaine-induced inhibition of fast Na+ currents in adult rat ventricular myocytes [@B26]. In addition, an aqueous-phase solution containing bupivacaine (without lipid emulsion) obtained through ultracentrifugation attenuated the blockade of the fast Na+ current compared with that of the fast Na+ current induced by bupivacaine alone [@B26]. Bupivacaine promoted the lipid emulsion-mediated reversal of the fast Na+ current blockade better than mepivacaine [@B26]. Other *in vitro* studies have investigated the binding of lipid emulsions to local anesthetics and support the lipid sink theory [@B23],[@B27],[@B28]. The binding capacity of lipid emulsion (Intralipid® and Medialipid®) to bupivacaine was found to be higher than that to ropivacaine, and the magnitude of the lipid emulsion-mediated reduction in serum concentration of local anesthetics was reportedly positively correlated with the lipid solubility of local anesthetics (bupivacaine \> ropivacaine \> mepivacaine) [@B23],[@B27],[@B28]. A toxic dose of local anesthetics, including bupivacaine, levobupivacaine, ropivacaine, lidocaine and mepivacaine, produced severe vasodilation in isolated endothelium-denuded rat aorta pre-contracted with the tyrosine phosphatase inhibitor sodium orthovanadate or the voltage-operated calcium channel activator KCl (60 mM) [@B29]-[@B31]. In contrast, lipid emulsion (Intralipid®, SMOFlipid® and Lipofundin® MCT/LCT) reversed the toxic dose of local anesthetic-induced vasodilation in a lipid solubility-dependent manner for local anesthetics (bupivacaine \> ropivacaine \> lidocaine \> mepivacaine) [@B23],[@B29]-[@B31]. In isolated endothelium-denuded rat aorta pre-contracted with the protein kinase C activator phorbol 12,13-dibutyrate or the Rho-kinase activator NaF, lipid emulsion (Intralipid®) attenuated bupivacaine-induced vasodilation [@B32],[@B33]. In contrast, lipid emulsion had no effect on mepivacaine-induced vasodilation [@B32],[@B33]. SMOFlipid® enhanced the norepinephrine-mediated reversal of vasodilation induced by a toxic dose of local anesthetic in a lipid solubility-dependent manner [@B34]. Similar to previous reports that focused on cardiac arrest and depression induced by a toxic dose of bupivacaine, all lipid emulsion-mediated reversals or inhibitions of severe vasodilation induced by toxic doses of local anesthetic of isolated aorta observed in these previous studies were positively correlated with the lipid solubility of local anesthetics [@B13],[@B18]-[@B21],[@B23],[@B24],[@B29]-[@B34]. These previous reports suggest that lipid emulsion-mediated reversal or inhibition helps to mitigate the severe vasodilation (vascular collapse) induced by toxic doses of local anesthetics [@B29]-[@B34]. The magnitude of lipid emulsion (SMOFlipid®)-mediated attenuation of apoptosis induced by toxic doses of local anesthetics was higher for bupivacaine than for mepivacaine [@B35]. This study suggests that the inhibition of apoptosis induced by lipid emulsion was associated with the lipid solubility of local anesthetics [@B23],[@B35]. Based on a physiologically-based pharmacokinetic model, lipid emulsion produced an only 11% reduction in the bupivacaine concentration in the heart within 3 min following lipid emulsion treatment and an 18% reduction in the bupivacaine concentration in the brain within 15 min [@B36]. Moreover, although a non-toxic dose of bupivacaine infusion in humans was used in a previous study, free bupivacaine concentrations did not significantly differ between the lipid emulsion and control groups [@B37]. However, the context-sensitive half-life of the total plasma bupivacaine concentration reportedly decreased in the lipid emulsion group, suggesting an enhanced distribution of bupivacaine throughout the tissue [@B37]. Lipid emulsion decreased the elimination half-life of bupivacaine and increased the initial bupivacaine content in the liver [@B38]. Lipid emulsion decreased the organ-to-blood ratio of bupivacaine in the cerebellum, frontal lobe, kidney and lung and enhanced the redistribution of bupivacaine into the liver [@B39]. Oher studies showed that lipid emulsion had no effect on the subjective symptoms induced by the central nervous system toxicity of lidocaine or the onset time of early signs associated with central nervous system toxicity induced by local anesthetics (ropivacaine and levobupivacaine) [@B40],[@B41]. However, lipid emulsion decreased the mean area under unentrapped lidocaine concentration-time curves and peak local anesthetic concentration [@B40],[@B41]. Lipid emulsion decreased the bispectral index but did not affect the duration of anesthesia [@B42]. These previous studies suggest that lipid emulsion can contribute to enhanced redistribution of local anesthetics or enhanced delivery of local anesthetics into the liver, which has been described as a lipid shuttle or subway [@B36]-[@B43]. Furthermore, lipid emulsion could reportedly mitigate the cardiovascular depression induced by toxic doses of local anesthetics (e.g., ropivacaine, lidocaine and mepivacaine) other than bupivacaine, with a relatively lower lipid solubility than that of bupivacaine [@B23],[@B44]-[@B48]. These results suggest that mechanisms (e.g., lipid shuttle) other than lipid sink partially contribute to lipid emulsion-mediated resuscitation [@B44]-[@B48]. Thus, lipid sink and shuttle associated with the capture and redistribution of local anesthetics could concomitantly contribute to the lipid emulsion-mediated recovery of local anesthetic toxicity.

Local anesthetics, including bupivacaine, ropivacaine and lidocaine, inhibited carnitine-stimulated pyruvate oxidation in cardiac mitochondria through the inhibition of carnitine-acylcarnitine translocase [@B10]. Fatty acid oxidation provided by lipid emulsion contributed to recovery from bupivacaine-induced cardiac depression in rats [@B49]. Furthermore, pretreatment with ATP abolished the myocardial depression induced by bupivacaine in an isolated rabbit right atrial model [@B50]. Lipid emulsion attenuated apoptosis induced by toxic doses of bupivacaine through inhibition of the bupivacaine-induced enhanced oxidative stress and mitochondrial dysfunction in H9c2 rat cardiomyoblasts [@B51],[@B52]. These results appear to be associated with inhibition of the mitochondrial permeability transition pore opening [@B51],[@B52]. These previous reports suggest that lipid emulsion-mediated recovery from bupivacaine-induced cardiac toxicity was associated with the reversal of the reduced fatty acid supply and ATP production or the mitochondrial dysfunction induced by toxic doses of bupivacaine [@B49]-[@B52]. In another study, lipid emulsion enhanced the mitochondrial respiratory function of myocardial cells and produced slight bupivacaine entrapment in bupivacaine-induced cardiac depression of pigs [@B53]. However, lipid emulsion did not improve the bupivacaine-induced decreased cardiac index [@B53].

Fettiplace et al. reported that Intralipid® increased the arterial pressure of rats and enhanced the rate of intraventricular pressure increases or decreases in an isolated rat heart model [@B54]. Lipid emulsion (Intralipid® and Lipofundin® MCT/LCT) increased the intracellular calcium level in H9c2 rat cardiomyoblasts [@B55]. Moreover, Intralipid® reversed the decreased left ventricular systolic pressure resulting from levobupivacaine-induced myocardial depression of isolated rat hearts using the Langendorff preparation [@B56]. These previous studies suggest that lipid emulsion has an intrinsic inotropic effect on the heart, with or without levobupivacaine-induced myocardial depression [@B54]-[@B56].

Postischemic reperfusion with lipid emulsion attenuated ischemia/reperfusion injury of the heart through the downstream kinase glycogen synthase kinase-3β (GSK-3β) phosphorylation mediated by upstream kinases, including either phosphoinositide 3-kinase (PI3K) and Akt or extracellular signal-regulated kinase [@B57]. This cellular signaling pathway led to the inhibition of the mitochondrial permeability transition pore opening [@B57]. Intralipid®-mediated resuscitation from bupivacaine-induced cardiac arrest in rats involves the activation of pathways associated with delta-opioid receptor and GSK-3β phosphorylation [@B58]. Bupivacaine toxicity induced phosphorylation of 5-adenosine monophosphate-activated protein kinase (AMPK) and inhibited Akt phosphorylation, which led to decreased activation of downstream kinases of mammalian target of rapamycin complex 1 [@B59]. However, in the presence of bupivacaine toxicity, lipid emulsion independently induced Akt phosphorylation without alteration of AMPK activation [@B59]. Lipid emulsion (Intralipid®) attenuated the apoptosis induced by toxic doses of bupivacaine or the calcium channel blocker verapamil in H9c2 rat cardiomyoblasts through a pathway involving either PI3K, Akt and GSK-3β or delta-opioid receptors, PI3K and Akt, respectively [@B60],[@B61]. Taken together, these reports suggest that the cellular signaling pathway downstream of Akt activated by lipid emulsion is associated with lipid emulsion-mediated recovery of bupivacaine toxicity [@B57]-[@B59].

Lipid emulsion attenuated acetylcholine-induced nitric oxide-mediated relaxation in isolated endothelium-intact rat aorta through inhibition of the nitric oxide-producing cellular signaling pathway proximal to guanylyl cyclase activation [@B62]. Local anesthetics, including levobupivacaine, ropivacaine and mepivacaine, caused vasoconstriction at lower doses and attenuated vasoconstriction (vasodilation) at higher doses in isolated rat aortas [@B63]-[@B65]. Local anesthetic-induced vasoconstriction was attenuated through endothelial nitric oxide production in endothelium-intact aortas compared with endothelium-denuded aortas [@B63]-[@B65]. Lipid emulsion reversed toxic doses of levobupivacaine-induced vasodilation through decreased nitric oxide bioavailability mediated by decreased caveolin-1 phosphorylation and reactive oxygen species [@B31],[@B66]. Furthermore, Intralipid® alone increased left ventricular systolic pressure in an *in vivo* rat model [@B67]. However, pretreatment with the nitric oxide synthase inhibitor N^W^-nitro-L-arginine methyl ester abolished the Intralipid®-mediated increase in left ventricular systolic pressure [@B67]. Considering previous reports, the lipid emulsion-mediated decreased bioavailability of nitric oxide released by toxic doses of local anesthetics may have partially contributed to the lipid emulsion-mediated reversal of vascular collapse from toxic doses of local anesthetic [@B31],[@B62]-[@B67]. Intralipid® facilitated recovery from cardiovascular depression induced by bupivacaine in pigs through increased systemic vascular resistance [@B53]. Moreover, in a human study, Intralipid® increased blood pressure and systemic vascular resistance and decreased vascular compliance [@B68]. Considering previous reports, the increased systemic vascular resistance induced by lipid emulsion observed in previous studies involving humans and pigs may have been due to lipid emulsion-mediated inhibition of endothelial nitric oxide [@B53],[@B62],[@B67],[@B68]. Mixed medium- and long-chain triglycerides reportedly increased systemic vascular resistance and decreased ventricular performance in awake dogs, whereas long-chain triglycerides alone did not significantly change systemic vascular resistance [@B69]. The Lipofundin® MCT/LCT-mediated inhibition of acetylcholine-induced nitric oxide-promoted relaxation was greater than Intralipid®-mediated inhibition; therefore, the abovementioned previously reported results may have been due to mixed medium- and long-chain triglyceride-mediated enhanced inhibition of nitric oxide-induced relaxation compared with long-chain triglycerides alone [@B62],[@B69]. Compared with normal pH values (7.4), mild acidification (pH 7.2) enhanced the lipid emulsion-mediated reversal of vasodilation induced by toxic doses of levobupivacaine, which is associated with lipid emulsion-induced inhibition of acidification-induced enhanced nitric oxide release [@B70]. In a study of acidification-mediated changes in the lipid emulsion\'s affinity for local anesthetics, acidification (pH 6.9) in human serum caused no significant change in the lipid emulsion-induced reduction in bupivacaine concentration [@B28]. However, acidification (pH 7.0) in buffer decreased the affinity of lipid emulsion to bupivacaine by 1.68-fold [@B27]. The clinical cardiovascular collapse induced by toxic doses of local anesthetics is followed by metabolic and respiratory acidosis, which leads to increased levels of free (not protein bound) and ionized local anesthetics [@B71],[@B72]. Thus, further study is needed to investigate the *in vivo* effect of acidosis on lipid emulsion-mediated resuscitation on the cardiovascular collapse induced by toxic doses of local anesthetic.

Lipofundin® MCT/LCT reduced the availability of cardiac sodium channels (Nav1.5) in human embryonic kidney (HEK)-293 cells expressing Nav1.5, whereas Intralipid® and Lipofundin® MCT/LCT partially reversed the blockade of bupivacaine-induced cardiac sodium channels [@B73]. The polyunsaturated fatty acid linolenic acid (18:3n-3) and the saturated fatty acid stearic acid (18:0), both of which are found in Intralipid®, attenuated the sodium current in HEK-293 cells expressing human cardiac sodium channels [@B74]. They also reversed the bupivacaine-induced sodium channel blockade in HEK-293 cells [@B74]. These results suggest that the fatty acids contained in lipid emulsion may modulate the cardiac sodium channel inhibited by local anesthetics through direct or indirect action [@B73]-[@B75].

In summary, although the lipid sink and shuttle mechanism is widely considered responsible for lipid emulsion resuscitation, the abovementioned mechanisms, including fatty acid supply, reversal of mitochondrial dysfunction, inotropic effect, GSK-3β phosphorylation, inhibition of nitric oxide release and reversal of cardiac sodium channel blockade, seem to be collectively involved in the resuscitation of cardiovascular collapse induced by toxic doses of local anesthetics [@B6]. Thus, it is very difficult to completely separate each individual proposed mechanism. For example, it is difficult to disentangle lipid emulsion-mediated reversal of mitochondrial dysfunction, cardiac sodium channel blockade and apoptosis from lipid sink and shuttle. The major free fatty acids involved in each of the proposed mechanisms responsible for the lipid emulsion-mediated resuscitation of local anesthetic systemic toxicity have not yet been determined. This information may be helpful for developing a specific lipid emulsion as an antidote for local anesthetic systemic toxicity.

What is the best lipid emulsion for reversal of local anesthetic toxicity?
==========================================================================

Intralipid® 20% and Lipovenoes® 20% contain 100% long-chain triglycerides made from soybean oil [@B76],[@B77]. The long-chain fatty acids contained in Intralipid® include 53% linoleic acid, 24% oleic acid, 11% palmitic acid, 8% alpha-linolenic acid and 4% stearic acid [@B76]. Lipofundin® MCT/LCT 20% and Medialipid® 20% contain 50% medium-chain triglycerides made from coconut oil and 50% long-chain triglycerides made from soybean oil [@B76]. The medium-chain fatty acids contained in Lipofundin® MCT/LCT 20% include 28.5% caprylic acid, 20% capric acid, 1% lauric acid and 0.5% caproic acid [@B76]. The long-chain fatty acids contained in Lipofundin® MCT/LCT 20% include 29.1% linoleic acid, 11% oleic acid, 7.4% palmitic acid, 4.5% alpha-linolenic acid and 2% stearic acid [@B76]. SMOFlipid® 20% includes 30% soybean oil, 30% coconut oil, 25% olive oil and 15% fish oil [@B76]. ClinOleic® 20% includes 20% soybean oil and 80% olive oil [@B1].

The binding capacity of Intralipid® to bupivacaine in the buffer solution is 2.5-fold higher than that of Medialipid® [@B27]. Conversely, Lipofundin® MCT/LCT absorbs more bupivacaine from serum than does Intralipid® [@B28]. A previous study showed that Intralipid® 20% and ClinOleic® 20% did not significantly differ in the magnitude of the reduction in bupivacaine concentration (induced by lipid emulsion) in the buffer [@B78]. Lipofundin® MCT/LCT produced a greater reversal of toxic-dose bupivacaine-induced vasodilation in isolated rat aortas than Intralipid® [@B30]. These different results may be attributed to differences in the solution (buffer solution *versus* serum) and method (binding study *versus* tension study) and the small sample size [@B27],[@B28],[@B30],[@B78]. Intralipid® resulted in fewer incidences of recurrent asystole and lower myocardial bupivacaine concentrations from bupivacaine-induced cardiac arrest in rats than lipid emulsion with a mixture of 50% medium-chain and 50% long-chain triglycerides [@B79]. Pretreatment with the propofol contained in Intralipid® increased the time required to produce bupivacaine-induced cardiac arrest in rats compared with pretreatment with the propofol contained in Medialipid® [@B80]. Intralipid® (1%) attenuates the blockade of cardiac sodium channels induced by bupivacaine, whereas Lipofundin® MCT/LCT (1%) does not significantly alter it [@B73]. As recommended by the American Society of Regional Anesthesia and Pain Medicine, these results suggest that Intralipid® is better than lipid emulsion with a mixture of medium-chain and long-chain fatty acids in lipid emulsion-mediated resuscitation of bupivacaine toxicity [@B73],[@B79]-[@B81]. Lipid emulsion with 100% long-chain triglycerides alone and lipid emulsion with a mixture of 50% medium-chain triglycerides and 50% long-chain triglycerides did not significantly differ in the reversal of cardiac electrophysiological alterations (for example, prolongation of the His-ventricle interval and QRS period) induced by bupivacaine in anesthetized and mechanically ventilated piglets [@B82]. Intralipid® and Lipofundin® MCT/LCT equally reversed toxic doses of levobupivacaine-induced vasodilation of isolated endothelium-denuded rat aortas [@B66]. Other types of lipid emulsions, including Lipofundin® MCT/LCT, Medialipid® and SMOFlipid® (other than Intralipid®), can reportedly treat toxicity induced by local anesthetic and other drugs [@B83]-[@B85]. Thus, as the effects of two lipid emulsions on the recovery from toxic doses of bupivacaine-induced cardiovascular collapse are controversial, it remains to be determined which type of fatty acid (long-chain *versus* medium-chain) is more beneficial in a laboratory setting at simulating clinical cardiovascular collapse induced by toxic doses of local anesthetics.

The effect of epinephrine on lipid emulsion-mediated resuscitation
==================================================================

Lipid emulsion treatment after epinephrine (100 µg/kg) and vasopressin (1.5 U/kg) administration following chest compression did not improve the extent of return of spontaneous circulation (ROSC) compared with normal saline after bupivacaine-induced cardiac arrest in swine [@B86]. Moreover, compared with lipid emulsion alone, high doses of epinephrine (\>10 µg/kg) combined with lipid emulsion inhibited sustained ROSC in bupivacaine-induced cardiac arrest of rats and caused hyperlactatemia and severe acidosis [@B87]. These results suggest that high doses of epinephrine and vasopressin inhibit lipid emulsion-mediated resuscitation because high-dose epinephrine causes acidosis and less sustained ROSC [@B86]-[@B88]. Epinephrine administration immediately after lipid emulsion-mediated resuscitation or after the bolus administration of lipid emulsion in a bupivacaine-induced cardiac arrest rat model decreased the lung injury caused by epinephrine and improved survival compared with epinephrine administration before the bolus administration of lipid emulsion [@B89],[@B90]. Lipid emulsion alone (4 ml/kg) followed by continuous infusion of lipid emulsion (0.25 ml/kg/min), combined treatment with lipid emulsion (4 ml/kg followed by 0.25 ml/kg/min) and epinephrine (10 µg/kg, repeated every 3 min) or epinephrine (10 µg/kg, repeated every 3 min) alone equally improved ROSC following levobupivacaine-induced cardiovascular collapse in newborn piglets compared with controls [@B91]. For arrhythmia after ROSC, treatment with epinephrine alone or lipid emulsion plus epinephrine increased the number of arrhythmia events compared with lipid emulsion alone [@B91]. This result suggests that high doses (10 µg/kg) of epinephrine, with or without lipid emulsion, induce cardiac arrhythmia [@B91]. In cardiac arrest induced by toxic doses of local anesthetics, epinephrine improves coronary perfusion due to increased systemic vascular resistance and inotropic effects, which may contribute to the lipid emulsion-mediated removal of bupivacaine from the myocardium [@B92]. Epinephrine used in resuscitation exaggerates the arrhythmia caused by bupivacaine and induces lung injury [@B92]. Compared with lipid emulsion (2%) or epinephrine (0.15 µg/kg) alone, combined treatment with lipid emulsion (Intralipid® 2%) and epinephrine (0.15 µg/kg) resulted in better recovery of the rate pressure product (cardiac function) from bupivacaine-induced cardiac asystole in isolated rat hearts using the non-recirculating Langendorff preparation [@B93]. Furthermore, Intralipid® (5 ml/kg followed by 0.5 ml/kg/min) improved the rate pressure product and metabolic parameters (pH, lactate level, and central venous oxygen saturation) in bupivacaine-induced cardiac arrest in rats compared with epinephrine alone (30 µg/kg) [@B94]. Thus, these previous studies suggest that a low dose of epinephrine may be beneficial in the lipid emulsion-mediated resuscitation of cardiac arrest induced by bupivacaine, as recommended by the American Society of Regional Anesthesia and Pain Medicine [@B81],[@B92]-[@B94]. Combined treatment with epinephrine (45, 45 and 200 µg/kg) and vasopressin (0.4, 0.4 and 0.8 U/kg) administered every 5 min improved survival following cardiac arrest induced by bupivacaine followed by hypoxia in a porcine model compared with lipid emulsion (Intralipid®: 4 ml/kg followed by 0.5 ml/kg/min) alone [@B95]. In contrast, Weinberg et al. reported that lipid emulsion (Intralipid®) enhanced survival of bupivacaine-induced circulatory arrest in dogs compared with saline [@B14]. This difference may be due to the different experimental methods (toxic dose of bupivacaine followed by hypoxia *versus* toxic dose of bupivacaine alone) and species (pig *versus* dog) employed. Hypoxia and acidosis potentiate local anesthetic toxicity [@B81]. Thus, as recommended by the American Society of Regional Anesthesia and Pain Medicine, hypoxia and acidosis at the early stages of local anesthetic toxicity should be prevented by supplying the airway with 100% oxygen [@B81]. The different results regarding the addition of epinephrine to the lipid emulsion used to treat cardiac arrest caused by local anesthetic systemic toxicity may be attributed to the experimental method (without hypoxia *versus* with hypoxia), dosage of epinephrine, species (rats, dogs and pigs) and sample size. Because of the conflicting results regarding the effect of epinephrine on the lipid emulsion-mediated resuscitation of local anesthetic systemic toxicity, further studies are needed to investigate the effects of epinephrine (dosage, timing and method of administration) on lipid emulsion-mediated resuscitation in a laboratory setting, similar to the clinical cardiovascular collapse induced by toxic doses of local anesthetics.

Recommended lipid emulsion treatment of local anesthetic systemic toxicity
==========================================================================

If symptoms and signs of local anesthetic systemic toxicity, including dizziness, agitation, tachycardia and hypertension, are detected, the airway should be maintained to avoid hypoxia and acidosis because hypoxia and acidosis exaggerate local anesthetic toxicity [@B81]. Seizures should be treated with benzodiazepine (midazolam, 1 to 5 mg) [@B81]. If seizures are not controlled with benzodiazepine, a small dose of succinylcholine should be administered to reduce the risk of acidosis and hypoxia [@B81]. Acidosis and hypoxia observed during seizure may be due to enhanced lactate production, oxygen consumption and inadequate respiration [@B96]. Lipid emulsion can be used to treat the incipient stage of cardiovascular depression induced by local anesthetic systemic toxicity before the development of cardiac arrest due to local anesthetic toxicity [@B81],[@B83],[@B97],[@B98]. If cardiac arrest is caused by local anesthetic systemic toxicity, advanced cardiac life support should be administered [@B81]. If epinephrine is used to treat cardiac arrest induced by toxic doses of local anesthetic, a small dose (10 to 100 µg) of epinephrine is preferred [@B81]. Vasopressin is not recommended [@B81]. If ventricular arrhythmia occurs, amiodarone is administered; treatment using local anesthetics (lidocaine or procainamide) is not recommended [@B81]. The following lipid emulsion treatment for local anesthetic systemic toxicity is recommended by the American Society of Regional Anesthesia and Pain Medicine and Association of Anaesthetists of Great Britain and Ireland: 1) a bolus administration (1.5 ml/kg based on lean body mass) of Intralipid® 20% over 1 min, followed by a continuous infusion (0.25 ml/kg/min based on lean body mass) of Intralipid® 20%, which should be continuously infused for at least 10 min after hemodynamic stability is obtained; 2) if hemodynamic stability is not obtained, a maximum of two repeated boluses of Intralipid® 20% (1.5 ml/kg) followed by continuous infusion of Intralipid® 20% with an increased dosage (0.5 ml/kg/min) should be considered; and 3) Intralipid® 20% at approximately 10 ml/kg for 30 min is the recommended upper limit of the initial dosage [@B81],[@B99]. For example, a rough estimate of the initial dosing regimen of Intralipid® 20% in a patient with a 70 kg body weight, which is easily remembered, is as follows: intravenous bolus administration (100 ml) of Intralipid® 20% over 1 min, followed by continuous infusion (1000 ml/hr) of Intralipid® 20% [@B99]. Cardiopulmonary resuscitation and oxygenation should be maintained during lipid emulsion infusion in cases of cardiac arrest due to local anesthetic toxicity. If the patient does not respond to the lipid emulsion and vasopressor treatment, cardiopulmonary bypass should be initiated [@B81],[@B99].

The early but less frequent adverse effects of Intralipid® include hyperlipidemia, dyspnea, allergic reaction, hypercoagulability and irritation [@B100]. The delayed less frequent adverse effects of Intralipid® include hepatomegaly, thrombocytopenia, splenomegaly, and transient elevation of liver function test values [@B100]. The side effects of lipid emulsion treatment used as parenteral nutrition include infection, hyperlipidemia, decreased immune response, acute pancreatitis, interference with laboratory examinations using serum, and parenteral nutrition-associated liver disease [@B1],[@B101]. Infection and hyperlipidemia may be associated with impaired reticuloendothelial function and lead to impaired pulmonary gas exchange, respectively [@B1]. However, the side effects induced by lipid emulsion infusion are mild and transient for a short-term infusion compared with the fatal complications, such as cardiovascular depression and cardiac arrest, induced by toxic doses of local anesthetic, which require immediate lipid emulsion treatment [@B4].

Conclusion
==========

Lipid emulsion administration is effective in treating cardiovascular collapse and central nervous system symptoms caused by local anesthetic toxicity, including that of bupivacaine, levobupivacaine, ropivacaine, lidocaine and mepivacaine. Moreover, lipid emulsion may be effective in alleviating intractable cardiovascular collapse induced by toxic doses of non-local anesthetic drugs, including calcium channel blockers (verapamil), tricyclic antidepressants (amitriptyline) and beta-blockers, which is reflected in case reports of successful lipid emulsion treatment for the toxicity caused by non-local anesthetic drugs [@B2],[@B3],[@B102].
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